Biomarin Pharma Incorporated (NASDAQ:BMRN) Stock Is Shorted Less

June 19, 2017 - By Henry Gaston

 Biomarin Pharma Incorporated (NASDAQ:BMRN) Stock Is Shorted Less

Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.62, from 1.66 in 2016Q3. It turned negative, as 50 investors sold BioMarin Pharmaceutical Inc. shares while 129 reduced holdings. 50 funds opened positions while 136 raised stakes. 165.79 million shares or 0.67% more from 164.68 million shares in 2016Q3 were reported.
Orbimed Ltd Com holds 1.27 million shares or 1.34% of its portfolio. Ray Gerald L And Assoc Ltd has 10,225 shares. State Street reported 3.74 million shares or 0.03% of all its holdings. Delta Lloyd Nv invested 0.04% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Calamos Wealth Limited Liability Corporation stated it has 14,625 shares or 0.2% of all its holdings. Capital One Natl Association has 0.06% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 2,842 are owned by Mirae Asset Communication Ltd. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta accumulated 177,000 shares or 0.13% of the stock. Advsrs Asset Mgmt Inc has invested 0.04% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Raymond James Finance Svcs Advsr reported 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 6,386 are held by Finance Counselors Inc. Dupont Cap Management reported 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Schwab Charles Investment Mgmt Incorporated holds 0.02% or 254,189 shares. Clearbridge Ltd Liability accumulated 816,295 shares or 0.07% of the stock. Creative Planning owns 13,340 shares for 0.01% of their portfolio.

Since January 6, 2017, it had 0 insider buys, and 27 selling transactions for $16.87 million activity. 1,989 shares were sold by SPIEGELMAN DANIEL K, worth $182,908 on Wednesday, March 15. $441,900 worth of stock was sold by BIENAIME JEAN JACQUES on Wednesday, May 24. 9,471 shares were sold by Davis George Eric, worth $862,230. Mueller Brian sold $687,334 worth of stock or 7,482 shares. LAWLIS V BRYAN sold $712,500 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Wednesday, March 1.

The stock of Biomarin Pharma Incorporated (NASDAQ:BMRN) registered a decrease of 2.72% in short interest. BMRN’s total short interest was 7.48M shares in June as published by FINRA. Its down 2.72% from 7.68M shares, reported previously. With 1.29M shares average volume, it will take short sellers 6 days to cover their BMRN’s short positions. The short interest to Biomarin Pharma Incorporated’s float is 4.35%.

It closed at $88.49 lastly. It is down 5.29% since June 19, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

BioMarin Pharmaceutical Inc. is a biotechnology company. The company has market cap of $15.10 billion. The Firm develops and commercializes pharmaceuticals for various diseases and medical conditions. It currently has negative earnings. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 20 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. BioMarin Pharmaceutical has $175 highest and $92 lowest target. $121.11’s average target is 36.86% above currents $88.49 stock price. BioMarin Pharmaceutical had 43 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Wedbush given on Tuesday, September 1. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Outperform” rating by Leerink Swann on Tuesday, February 23. The firm earned “Overweight” rating on Friday, August 5 by Piper Jaffray. The company was maintained on Friday, August 5 by Stifel Nicolaus. The stock has “Outperform” rating by Credit Suisse on Wednesday, January 20. The rating was initiated by Gabelli with “Buy” on Thursday, December 8. The firm has “Neutral” rating given on Monday, November 7 by Piper Jaffray. Jefferies maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Wednesday, May 31. Jefferies has “Buy” rating and $11600 target. Wedbush maintained the stock with “Neutral” rating in Monday, October 5 report. The stock has “Buy” rating by William Blair on Wednesday, August 5.

More important recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Zacks.com which released: “BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?” on June 08, 2017, also Streetinsider.com published article titled: “BioMarin Pharma (BMRN) Announces Acceptance of Late Breaking Abstract at ISTH”, Prnewswire.com published: “European Commission Approves Brineuraâ„¢ (cerliponase alfa), the First …” on June 01, 2017. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was released by: Prnewswire.com and their article: “BioMarin to Attend Upcoming Investor Conference” with publication date: May 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.